NCT02711137 2025-10-21Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced MalignanciesIncyte CorporationPhase 1/2 Terminated137 enrolled 31 charts
NCT02663518 2024-05-10A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid TumorsPfizerPhase 1 Terminated249 enrolled 43 charts
NCT02431260 2019-06-14An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced MalignanciesIncyte CorporationPhase 1/2 Terminated69 enrolled 34 charts